SCHEMBL2856685

SCHEMBL2856685

O=C(NCc1ccc(F)cc1)C1CNCC2C(=O)OC(c3cccc(F)c3)(c3cccc(F)c3)N12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.49
ALDH1A1 P00352 4/20 0.42
CACNA1G O43497 1/20 0.39
THRB P10828 1/20 0.39
ADRB2 P07550 1/20 0.39
APLNR P35414 1/20 0.39
GLP1R P43220 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
METAP2 P50579 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
P2RX7 Q99572 2/20 0.38
KCNN4 O15554 1/20 0.38
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856315 0.91 NPSR1 (0.58) NPSR1ALDH1A1CACNA1GADRB2APLNR
SCHEMBL2865812 0.90 NPSR1 (0.51) NPSR1ALDH1A1CACNA1GMEN1KMT2A
SCHEMBL2861757 0.90 NPSR1 (0.47) NPSR1ALDH1A1THRBMETAP2KMT2A
SCHEMBL2864543 0.87 POLB (0.38) NPSR1MEN1KMT2AKCNN4TSHR
SCHEMBL2858851 0.84 NPSR1 (0.47) NPSR1ALDH1A1CACNA1GADRB2APLNR
SCHEMBL6039852 0.83 NPSR1 (0.36) NPSR1ALDH1A1MEN1KMT2AKCNN4
SCHEMBL2871764 0.83 NPSR1 (0.48) NPSR1ALDH1A1MEN1KMT2ATSHR
SCHEMBL2870790 0.83 NPSR1 (0.48) NPSR1ALDH1A1CACNA1GMETAP2MEN1
Hydrochloric Acid SCHEMBL2861673 0.83 NPSR1 (0.35) NPSR1ALDH1A1MEN1KMT2AKCNN4
SCHEMBL2867646 0.82 ALDH1A1 (0.45) NPSR1ALDH1A1CACNA1GMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 NPSR1 211/4885ALDH1A1 2926/4885CACNA1G 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.